{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T06:12:21Z","timestamp":1760249541696},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7-8","license":[{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T00:00:00Z","timestamp":1623110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Functional mitral regurgitation (FMR) can be subclassified based on its proportionality relative to left ventricular function and end-diastolic volume. FMR proportionality could help identify responders to transcatheter edge-to-edge mitral valve repair (MitraClip) in terms of residual FMR and\/or clinical improvement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This single-centre retrospective cohort study evaluated the feasibility of determining FMR proportionality in symptomatic heart failure patients with reduced left ventricular function who were treated with MitraClip for\u202f\u2265\u2009moderate-to-severe FMR. Baseline proportionate (pFMR) and disproportionate FMR (dFMR) were distinguished. Patient characteristics and MitraClip procedural outcomes were described.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From an overall cohort of 81\u00a0eligible FMR patients, 23\/81 (28%) had to be excluded due to missing transthoracic echocardiogram parameters, 22\/81 were excluded based on FMR severity. The remaining cohort, of 36\/81\u00a0patients (44%), could be classified into dFMR (<jats:italic>n<\/jats:italic>\u202f=\u200926) or pFMR (<jats:italic>n<\/jats:italic>\u202f=\u200910). Conduction disorders were numerically increased in dFMR. All cases requiring &gt;\u202f2\u00a0clips were in the dFMR group and absence of FMR reduction occurred more frequently with dFMR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Point of view\/Conclusion<\/jats:title>\n                <jats:p>Important limitations in terms of imaging acquisition affect the translation of the FMR proportionality concept to a\u00a0real-world data set. We did observe different demographic and FMR response patterns in patients with proportionate and disproportionate FMR that warrant further investigation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12471-021-01583-6","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T16:03:17Z","timestamp":1623168197000},"page":"359-364","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transcatheter mitral valve repair in proportionate and disproportionate functional mitral regurgitation\u2014insights from a\u00a0small cohort study"],"prefix":"10.1007","volume":"29","author":[{"given":"J. F.","family":"Ooms","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Geleijnse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Spitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Van Wiechen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. W.","family":"Hokken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Daemen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. P. T.","family":"de Jaegere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. M. D. A.","family":"Van Mieghem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,8]]},"reference":[{"key":"1583_CR1","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner\u00a0H, Falk\u00a0V, Bax\u00a0JJ, et\u00a0al. 2017 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart\u00a0J. 2017;38:2739\u201391.","journal-title":"Eur Heart J"},{"key":"1583_CR2","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.104.486720","volume":"112","author":"RA Levine","year":"2005","unstructured":"Levine\u00a0RA, Schwammenthal\u00a0E. Ischemic mitral regurgitation on the threshold of a\u00a0solution: from paradoxes to unifying concepts. Circulation. 2005;112:745\u201358.","journal-title":"Circulation"},{"key":"1583_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD, et\u00a0al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"1583_CR4","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","volume":"379","author":"GW Stone","year":"2018","unstructured":"Stone\u00a0GW, Lindenfeld\u00a0J, Abraham\u00a0WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N\u00a0Engl J Med. 2018;379:2307\u201318.","journal-title":"N Engl J Med"},{"key":"1583_CR5","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","volume":"379","author":"JF Obadia","year":"2018","unstructured":"Obadia\u00a0JF, Messika-Zeitoun\u00a0D, Leurent\u00a0G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N\u00a0Engl J Med. 2018;379:2297\u2013306.","journal-title":"N Engl J Med"},{"key":"1583_CR6","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1002\/ejhf.1616","volume":"21","author":"B Iung","year":"2019","unstructured":"Iung\u00a0B, Armoiry\u00a0X, Vahanian\u00a0A, et\u00a0al. Percutaneous repair or medical treatment for secondary mitral regurgitation: outcomes at 2\u00a0years. Eur J Heart Fail. 2019;21:1619\u201327.","journal-title":"Eur J Heart Fail"},{"key":"1583_CR7","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jcmg.2018.11.006","volume":"12","author":"PA Grayburn","year":"2019","unstructured":"Grayburn\u00a0PA, Sannino\u00a0A, Packer\u00a0M. Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials. JACC Cardiovasc Imaging. 2019;12:353\u201362.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1583_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1161\/CIRCULATIONAHA.119.039612","volume":"140","author":"M Packer","year":"2019","unstructured":"Packer\u00a0M, Grayburn\u00a0PA. Contrasting effects of pharmacological, procedural, and surgical interventions on proportionate and disproportionate functional mitral regurgitation in chronic heart failure. Circulation. 2019;140:779\u201389.","journal-title":"Circulation"},{"key":"1583_CR9","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/j.jcmg.2019.05.005","volume":"12","author":"PE Bartko","year":"2019","unstructured":"Bartko\u00a0PE, Heitzinger\u00a0G, Arfsten\u00a0H, et\u00a0al. Disproportionate functional mitral regurgitation: advancing a\u00a0conceptual framework to clinical practice. JACC Cardiovasc Imaging. 2019;12:2088\u201390.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1583_CR10","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-19-01114","author":"M Adamo","year":"2020","unstructured":"Adamo\u00a0M, Cani\u00a0DS, Gavazzoni\u00a0M, et al. Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair. EuroIntervention. 2020; https:\/\/doi.org\/10.4244\/EIJ-D-19-01114.","journal-title":"EuroIntervention"},{"key":"1583_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/ejechocard\/jeq031","volume":"11","author":"P Lancellotti","year":"2010","unstructured":"Lancellotti\u00a0P, Moura\u00a0L, Pierard\u00a0LA, et\u00a0al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: mitral and tricuspid regurgitation (native valve disease). Eur J Echocardiogr. 2010;11:307\u201332.","journal-title":"Eur J Echocardiogr"},{"key":"1583_CR12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1093\/ehjci\/jet105","volume":"14","author":"P Lancellotti","year":"2013","unstructured":"Lancellotti\u00a0P, Tribouilloy\u00a0C, Hagendorff\u00a0A, et\u00a0al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14:611\u201344.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"1583_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jcmg.2013.07.014","volume":"7","author":"R Beigel","year":"2014","unstructured":"Beigel\u00a0R, Siegel\u00a0RJ. Should the guidelines for the assessment of the severity of functional mitral regurgitation be redefined? JACC Cardiovasc Imaging. 2014;7:313\u20134.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1583_CR14","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1016\/j.jacc.2014.10.016","volume":"64","author":"PA Grayburn","year":"2014","unstructured":"Grayburn\u00a0PA, Carabello\u00a0B, Hung\u00a0J, et\u00a0al. Defining \u201csevere\u201d secondary mitral regurgitation: emphasizing an integrated approach. J\u00a0Am Coll Cardiol. 2014;64:2792\u2013801.","journal-title":"J Am Coll Cardiol"},{"key":"1583_CR15","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/ejechocard\/jeq121","volume":"11","author":"S Ray","year":"2010","unstructured":"Ray\u00a0S. The echocardiographic assessment of functional mitral regurgitation. Eur J Echocardiogr. 2010;11:i11\u20137.","journal-title":"Eur J Echocardiogr"},{"key":"1583_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","volume":"30","author":"WA Zoghbi","year":"2017","unstructured":"Zoghbi\u00a0WA, Adams\u00a0D, Bonow\u00a0RO, et\u00a0al. Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance. J\u00a0Am Soc Echocardiogr. 2017;30:303\u201371.","journal-title":"J Am Soc Echocardiogr"},{"key":"1583_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1161\/01.CIR.79.4.845","volume":"79","author":"CL Grines","year":"1989","unstructured":"Grines\u00a0CL, Bashore\u00a0TM, Boudoulas\u00a0H, et\u00a0al. Functional abnormalities in isolated left bundle branch block. The effect of interventricular asynchrony. Circulation. 1989;79:845\u201353.","journal-title":"Circulation"},{"key":"1583_CR18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/echo.13782","volume":"35","author":"F Vancheri","year":"2018","unstructured":"Vancheri\u00a0F, Vancheri\u00a0S, Henein\u00a0M. Relationship between QRS measurements and left ventricular morphology and function in asymptomatic individuals. Echocardiography. 2018;35:301\u20137.","journal-title":"Echocardiography"},{"key":"1583_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1161\/CIRCULATIONAHA.105.543678","volume":"113","author":"GB Bleeker","year":"2006","unstructured":"Bleeker\u00a0GB, Kaandorp\u00a0TA, Lamb\u00a0HJ, et\u00a0al. Effect of posterolateral scar tissue on clinical and echocardiographic improvement after cardiac resynchronization therapy. Circulation. 2006;113:969\u201376.","journal-title":"Circulation"},{"key":"1583_CR20","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/eurheartj\/ehz306","volume":"40","author":"AHJ Petrus","year":"2019","unstructured":"Petrus\u00a0AHJ, Dekkers\u00a0OM, Tops\u00a0LF, et al. Impact of recurrent mitral regurgitation after mitral valve repair for functional mitral regurgitation: long-term analysis of competing outcomes. Eur Heart\u00a0J. 2019;40:2206\u201314.","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01583-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-021-01583-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01583-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T14:34:04Z","timestamp":1625841244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-021-01583-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,8]]},"references-count":20,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1583"],"URL":"https:\/\/doi.org\/10.1007\/s12471-021-01583-6","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,8]]},"assertion":[{"value":"3 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.M.D.A.\u00a0Van Mieghem has received a\u00a0research grant support from Boston Scientific, Edwards Lifesciences, Abbot Vascular and PulseCath\u00a0B.V. which were received for activities outside the submitted work. J.\u00a0Daemen received institutional grant\/research support from AstraZeneca, Abbott Vascular, Boston Scientific, ACIST Medical, Medtronic, Pie Medical, ReCor medical and PulseCath, and consultancy and speaker fees from ACIST medical, Boston Scientific, ReCor Medical, Pie Medical, Medtronic and Pulse Cath. J.F.\u00a0Ooms, M.L.\u00a0Geleijnse, E.\u00a0Spitzer, B.\u00a0Ren, M.P.\u00a0Van Wiechen, T.W.\u00a0Hokken and P.P.T.\u00a0de Jaegere declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}